CDK5 and prostate cancer: Our results demonstrated that Roscovitine treatment significantly suppressed AR protein activation, AR subcellular translocation, transcriptional activity, and cell proliferation in prostate cancer cells, which was strongly correlated to CDK5 actions [83].